



# Tricare has expanded CGM coverage for all insulin users<sup>1</sup>



The patient has a diagnosis of T1 diabetes or T2 diabetes mellitus, and one of the following situations applies<sup>2</sup>:


Patient is using basal and prandial insulin injections,

OR

Patient is using a continuous subcutaneous insulin infusion (ie, insulin pump),

OR

Patient has Type 2 diabetes mellitus and is receiving insulin therapy and has a history of severe hypoglycemia episodes requiring medical intervention.



The patient has a diagnosis of diabetes and is currently being **treated with insulin**<sup>1</sup>.

**Automated PA:** The patient has filled a prescription for insulin during the **previous 180 days**\*<sup>1</sup>.


DHA = Defense Health Agency, PA=Prior Authorization

\* If automated criteria are not met, coverage is manually approved for FreeStyle Libre 2 systems and FreeStyle Libre 3 systems if all criteria are met.


**1.** Department of Defense Pharmacy and Therapeutics Committee Recommendations from the February 2024 meeting, <https://health.mil/Reference-Center/Meeting-References/2024/03/27/UF-BAP-Background-Document-April-3-2024-time-zone-edited>. Accessed May 9, 2024. **2.** Department of Defense Pharmacy and Therapeutics Committee Recommendations from the November 2022 Meeting Information for the Uniform Formulary Beneficiary Advisory Panel, <https://www.health.mil/Reference-Center/Meeting-References/2022/12/16/BAP-Background-Document-for-the-Nov-2022-PT-Meeting>. Accessed May 17, 2024.

See last page for **Important Safety Information**.

Only about 1 in 5 insulin users in the US are at their A1c goal of <7%<sup>1,2</sup>



Reductions in A1c were observed in people with diabetes across treatment regimens after using FreeStyle Libre systems<sup>†‡3-4,§||5-6</sup>



Help your insulin users achieve better outcomes  
with FreeStyle Libre CGM systems

Abbott provides this information as a courtesy and does not guarantee payment or coverage.

T1D: type 1 diabetes; T2D: type 2 diabetes; MDI: multiple daily injections

\* 2016-2018 data. † 2012-2015 data. ‡ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products.

§ Data from this study was collected with the US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre system 14 day with real-time glucose alarms. Therefore the study data is applicable to both products. || Data from this study was collected with the US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products. ¶ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products. # Baseline A1c between 8% and 12%.

1. Foster, N. *Diabetes Tech Ther* (2019). <https://doi.org/10.1089/dia.2018.0384>. 2. Brixner, D. *Clinical Ther* (2019). <https://doi.org/10.1016/j.clinthera.2018.12.014>. 3. Tyndall, V. *Diabetologia* (2019): <https://doi.org/10.1007/s00125-019-4894-1>. 4. Kroger, J. *Diabetes Ther* (2020): <https://doi.org/10.1007/s13300-019-00741-9>. 5. Carlson, A. *BMJ Open Diabetes Res Care* (2022). <https://doi.org/10.1136/bmjdr-2021-002590>. 6. Wright, E. *Diabetes Spectr* (2021). <https://doi.org/10.2337/ds20-0069>.

#### Important Safety Information

**FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems:** Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or <https://www.FreeStyle.abbott/us-en/safety-information.html> for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. © 2024 Abbott. ADC-92237 v2.0